Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Phase 2
Recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 20
- Registration Number
- NCT06608732
- Locations
- 🇨🇳
National Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Phase 2
Recruiting
- Conditions
- Acute Lymphoblastic Leukemia ALL
- Interventions
- Biological: Autologous hematopoietic stem cell transplantation combined with CD19-CART
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Target Recruit Count
- 20
- Registration Number
- NCT06608342
- Locations
- 🇨🇳
NO.288 Nanjing Road，Heping District，Tianjin, Tianjin,, Tianjin, Tianjin, China
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 108
- Registration Number
- NCT06594640
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Tislelizumab with Azacitidine in the Treatment of R/R AML
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 20
- Registration Number
- NCT06570915
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
Phase 1
Not yet recruiting
- Conditions
- FLT3 Gene MutationAML
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 36
- Registration Number
- NCT06561880
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase 1
Active, not recruiting
- Conditions
- Small Lymphocytic LymphomaChronic Lymphocytic LeukemiaNewly Diagnosed
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 30
- Registration Number
- NCT06547944
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2
Recruiting
- Conditions
- T-LGL LeukemiaLymphoma, T-CellNK-LGL Leukemia
- Interventions
- Drug: PI3K inhibitor
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 51
- Registration Number
- NCT06530550
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
Not Applicable
Recruiting
- Conditions
- AML
- Interventions
- Drug: HADDrug: Daunorubicin+Cytarabine
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-01-16
- Target Recruit Count
- 148
- Registration Number
- NCT06529250
- Locations
- 🇨🇳
Blood Hospital, Tianjin, Tianjin, China
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Phase 2
Recruiting
- Conditions
- NK-LGL LeukemiaT-LGL Leukemia
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 48
- Registration Number
- NCT06530576
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath